-
New Data Suggests a More Expansive View of Heart Health Lipids
Nov 04 | Bio-IT World | The traditional LDL and HDL cholesterol tests may soon be obsolete as new research suggests they provide an incomplete view of heart health compared to other lipid molecules circulating in the blood. This shift stems from a recent study led by Dr. Cristina Legido-Quigley, a systems medicine expert at King’s College London and Steno Diabetes Centre, which analyzed lipids in children with obesity. More -
AI Points to Drug Repurposing Opportunities for Diseases Without Cures
Oct 31 | Bio-IT World | Harvard scientists have succeeded in using artificial intelligence (AI) to identify promising drug candidates for diseases for which there are no examples of successful treatment. The graph foundation model, known as TxGNN, opens untold opportunities to repurpose drugs for the thousands of diseases afflicting small populations and exacting a huge toll in terms of both economics and human suffering. More -
New 10x Instruments, Merck Acquires Modifi Biosciences, New Immunogenicity Bioanalysis Features, Partnerships, More
Oct 30 | Bio-IT World | Modifi Biosciences has been acquired by Merck; Sapio Sciences announces the addition of new immunogenicity bioanalysis features to its industry-leading lab informatics platform; and more. More -
Follow the Money: Small Molecule Solutions AI Platform, MIT, Basecamp Research Collaboration, More
Oct 29 | Bio-IT World | Terray Therapeutics will enhance their integrated AI platform, tNova, which identifies and optimizes novel small molecule solutions to the most complex problems; Basecamp Research, in collaboration with the laboratory of Dr. David R. Liu at the Broad Institute of MIT and Harvard, plans to advance their data collection and strengthen their AI capabilities; and more. More -
AI Is Nothing Without An AI-Ready Data Strategy
Oct 25 | Bio-IT World | Applied artificial intelligence (AI) is already transforming drug discovery research and development, accelerating the journey from lab to lifesaving therapies, and both the reality and the hype are very well known. Less obvious—almost 90% of the iceberg—is the critical role played by data. More -
Cleveland Clinic Researchers Find Hope in Immune Cells’ Reaction to Immunotherapy
Oct 23 | Bio-IT World | There is much we still don’t know about the relationship between immune cells and cancer cells and how they interact and influence each other over the course of immune activating cancer therapies. Researchers at Cleveland Clinic are exploring these relationships and reported their results last month in Nature Medicine. More -
Illumina’s New Desktop Sequencing Series Is Fast, Cheap, Simple
Oct 17 | Bio-IT World | Illumina unveiled its MiSeq i100 Series of sequencing systems last week during an online customer event, comprising two new benchtop instruments: MiSeq i100 and MiSeq i100 Plus Systems. The MiSeq i100 will be available to ship globally in 2025. More -
Pistoia Alliance Research Finds Concerns on Security, Barriers, More
Oct 16 | Bio-IT World | As artificial intelligence (AI) and machine learning (ML) become increasingly prevalent in the industry, there are still several concerns about its implementation. Mainly, how safe is it to use AI? What measures can be taken to increase and reinforce security? The Pistoia Alliance decided to find out. More -
‘Heretical’ Idea for Treating Triple-Negative Breast Cancer Moves Forward
Oct 15 | Bio-IT World | The clinical utility of treating cancer by modulating the estrogen receptor could radically and quickly expand, initially for patients with triple-negative breast cancer but potentially thereafter to those with melanoma and cancers found in the colon, lung, head, and neck. Hope springs from findings emerging from the lab of Professor Donald McDonnell, Ph.D., at Duke University School of Medicine, where the field of oral selective estrogen down-regulators was pioneered nearly two decades ago. More -
Building Digital Architecture to Reach New Heights: Data and Knowledge Management for Pharma 4.0
Oct 11 | Bio-IT World | In early 2024, it was revealed that contract research and manufacturing organization WuXi Apptec had allegedly shared intellectual property with the Chinese government without their client’s consent. This breach of trust generated widespread concern and backlash, bringing renewed attention to the importance of proper data management and data sharing in the biotech and pharmaceutical industries. More
Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and
data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!
Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!